In December 2025, Medtronic Plc notified healthcare providers to remove its Left Heart Vent Catheters from use and sale after identifying a manufacturing defect that prevents the catheter shaft from holding shape when bent. The affected lot numbers spanned three production batches totaling 12,450 units distributed across 45 hospital systems in North America and Europe. Medtronic reported zero patient fatalities but logged 42 adverse events, including four cases that required surgical intervention to reposition the catheter. The company has instructed facilities to quarantine remaining inventory, complete device traceability forms, and return units under the existing customer care program. Medtronic is collaborating with national regulatory authorities to complete a root-cause analysis and implement process controls by Q2 2026.

Medtronic is on track to raise its quarterly dividend per share for the 48th consecutive year in Q3 2026, underscoring its commitment to returning capital to shareholders. The current yield stands at approximately 2.6%, based on the last declared payment, and dividend increases have averaged 6.3% annually over the past decade. Key revenue drivers include the Pulsed Field Ablation franchise, which saw global procedure volume grow 32% year-over-year in Q4 2025, and the Symplicity renal denervation system for hypertension, where orders jumped 45% in the U.S. during fiscal 2025. Medtronic’s diversified portfolio and disciplined capital allocation have supported steady free cash flow generation, with $6.8 billion in free cash flow reported for fiscal 2025, enabling both strategic acquisitions and shareholder distributions.

Moody’s and S&P maintain Medtronic’s investment-grade credit ratings—Baa1 and A, respectively—with stable outlooks. As of December 31, 2025, total debt stood at $38.2 billion, representing a net debt-to-EBITDA ratio of 2.4x, within the company’s target range of 2.0x to 2.5x. Medtronic’s strong liquidity position includes $8.1 billion in cash and revolver capacity, supporting planned capital expenditures of $2.3 billion in fiscal 2026 and the integration of recent bolt-on acquisitions valued at $1.7 billion. The stable credit outlook reflects predictable cash flow streams from its global installed base of 60 million devices and ongoing efforts to improve operating margins by 150 basis points through 2027.